Visual and systemic outcomes in pediatric ocular myasthenia gravis.

S. Pineles,R. Avery,H. Moss,R. Finkel,T. Blinman,L. Kaiser,Grant T. Liu

DOI: https://doi.org/10.1016/j.ajo.2010.05.002

2010-10-01

Abstract:

What problem does this paper attempt to address?

Clinical Characteristics, Disease Course, and Outcomes of Paediatric Patients with Myelin Oligodendrocyte Glycoprotein-Ab Associated Disease: A Retrospective Clinical Study

Min Zhang,Xiaonan Du,Shuizhen Zhou,Gang Pan,Jin Shen,Wenhui Li,Lifei Yu,Yuanfeng Zhou,Yunjian Zhang,Yi Wang,Linmei Zhang

DOI: https://doi.org/10.1016/j.jocn.2021.09.035

IF: 2.116

2021-01-01

Journal of Clinical Neuroscience

Abstract:Objective: To delineate the outcomes of paediatric patients with myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Methods: We retrospectively analyzed the clinical characteristics, treatment, and outcomes of 34 paediatric patients with MOGAD from July 2015 to January 2020. Results: The median age at disease onset was 75.5 months (range: 19-170 months). The female-to-male ratio was 1:1.1. The median follow-up duration was 34.5 months (range: 14-63 months). Acute disseminated encephalomyelitis (ADEM) was the most common initial phenotype (52.9%), followed by optic neuritis (ON) (20.6%). Children with ADEM were younger than those with ON (P = 0.045). Twentyeight (82.4%) and 18 (56.3%) children had abnormal brain and spinal magnetic resonance imaging, respectively, during the first acute attack. MOG-abs titers in children with ON were statistically higher than those in children with ADEM (P = 0.04). Thirty-two children accepted glucocorticoid treatment, while 33 (97%) children demonstrated clinical improvement within 1 week, 21 children (61.8%) achieved clinical recovery within 1 month. Eight children (23.5%) suffered a relapse, the median interval between the initial attack and recurrence was 13 (range: 3-36) months. We detected neurological sequelae in seven (20.6%) children, with visual dysfunction being the most common sequela (85.7%). Conclusion: ADEM was the most common phenotype in both monophasic and relapsed paediatric MOGAD, followed by ON. Majority of pediatric MOGAD patients were highly responsive to glucocorticoid. Despite a benign prognosis in most patients, some patients endure neurological sequelae, mainly visual impairment. Patients with initial visual impairment should be carefully evaluated and administered individualized immunotherapy. (c) 2021 Elsevier Ltd. All rights reserved.
Treatment Outcomes and Predictive Factors in Pediatric Ocular Myasthenia Gravis

Parichat Kraithat,Linda Hansapinyo,Prapatsorn Patikulsila

Abstract:Objective: To determine demographic data, clinical presentations, investigations, treatment regimens, and clinical outcomes in pediatric ocular myasthenia gravis patients, and to find predictive factors for clinical outcomes such as resolution of disease, development of generalized symptoms, or final amblyopia. Material and method: This retrospective descriptive study of the medical records of 14 patients (male 6,female 8) less than 15 years that had ocular myasthenia gravis at Chiang Mai University Hospital between January 2006 and December 2012 was done. Univariate analysis was used to evaluate the predictive factors for clinical outcomes. Results: Mean age of onset was 6.96±4.65 years (range 0.58-14 years). All patients presented with ptosis (100%) and 67% with strabismus. The mean oftotalfollow-up time is 6.30±3.84 years (range 1.25-14.25 years). None ofthe patients developed generalize myasthenia gravis. Only one patient had amblyopia at final presentation. Presenting age, gender strabismus at initial presentation, and positive neostigmine or edrophonium test did not affect resolution of disease nor final amblyopia. Conclusion: The most common clinical presentation in pediatric OMG was ptosis. Most patients could control the disease only by medications. There were no predictive factors affecting resolution of disease nor final amblyopia.
Pediatric Ocular Myasthenia Gravis: Single-Center Experience

Miriam Kessi,Yulin Tang,Baiyu Chen,Guoli Wang,Ciliu Zhang,Fang He,Jing Peng,Fei Yin,Lifen Yang

DOI: https://doi.org/10.1016/j.pediatrneurol.2024.01.014

IF: 4.21

2024-02-22

Pediatric Neurology

Abstract:Background Currently, there is no universally accepted standard treatment for ocular myasthenia gravis (OMG) in children. We aimed to investigate the possible proper regimens and timing of treatment for pediatric OMG cases based on the clinical manifestations: OMG with ptosis only and OMG with other features. Methods One hundred and forty two OMG cases attended at the Department of Pediatrics, Xiangya Hospital, Central South University, from 2010 to 2019 were included, and information from medical records was reviewed and recorded. Comparisons of clinical characteristics between patients with OMG with ptosis only and patients with OMG with other features as well as between patients treated with glucocorticoid (GC) within or after six months from disease onset were performed. Results OMG with other features constituted about 54.9% of the cases, and 66.2% of the patients achieved optimal outcome. Patients with OMG with ptosis only responded to pyridostigmine alone more than patients with OMG with other features who required several therapies ( P < 0.001). Patients with OMG with ptosis only had a larger proportion of optimal outcome than the patients with OMG with other features ( P = 0.002), and the difference remained significant even when the individual outcome groups were compared ( P < 0.001). Patients who received GC within six months had a greater proportion of optimal outcome than those who received it after six months ( P < 0.001). Conclusions Although OMG with other features is a more common subtype of OMG, it is also more severe than OMG with ptosis only. An earlier addition of GC leads to optimal outcome.

pediatrics,clinical neurology
[Pediatric myasthenia with ocular involvement]

L Prud'homme,C Gitiaux,C Barnerias,C Orssaud,D Bremond-Gignac,M P Robert

DOI: https://doi.org/10.1016/j.jfo.2024.104202

Abstract:Purpose: Myasthenia is a rare disease in children, with an estimated incidence of 1 to 5 per million children. However, the potential severity of its consequences and the existence of specific treatments require prompt diagnosis by pediatric ophthalmologists. Methods: Retrospective review of patient records. Patients were identified from a rare disease database. Patients under the age of 18 years with confirmed diagnosis of myasthenia and ocular symptoms seen in a specialized clinic between 2005 and 2021 were included. Results: Twenty-six (16 girls) with confirmed myasthenia and ocular symptoms were included. Ten patients had definite autoimmune myasthenia gravis (AIMG); 6 had suspected AIMG with negative antibody testing. Six patients had definite congenital myasthenic syndrome (CMS); 4 had suspected CMS with no evidence of mutation. Mean age at diagnosis of myasthenia was 5 years-3 years and 5 months for CMS and 6 years and 3 months for AIMG. Male to female (M:F) ratio was 6/10 for autoimmune myasthenia gravis and 4/6 for CMS. Ptosis was present in all cases; strabismus in 21 patients (68%). The clinical forms of myasthenia were ocular myasthenia in 12 patients (10 AIMG and 2 CMS), generalized in 12 patients (7 CMS and 5 AIMG) and secondary generalization of ocular myasthenia in 2 patients (2 AIMG). Discussion: These results are based on only 26 cases, which can be explained by the rarity of this diagnosis in children. As in adults, the first signs are often ophthalmologic - ptosis alone or associated with strabismus. Diagnosis is difficult because of the absence of clinical signs, laboratory tests or electrophysiological signs with high sensitivity. Thus, the work-up may remain completely negative in secondarily proven forms. In addition, electroneuromyograms and oculomotor recordings in small children are more difficult to perform than in adults. For these reasons, the clinical examination is essential. In the case of strong suspicion, all additional medical examinations are carried out in a day unit, in order to reach a positive diagnosis of myasthenia. The so-called "congenital" forms, which are genetic, are proportionately higher than in adults, and diagnosis and treatment are often more difficult than in the classic autoimmune forms. Conclusion: Myasthenia can affect children from a very young age and can present as ptosis, initially isolated or associated with strabismus. Diagnosis and treatment may be difficult and should be organized in specialized centers.
A single-center retrospective series of OCT and MRI findings in pediatric MOGAD optic neuritis patients

Ridhima Guniganti,Shinji Rho,Juan F Morales-Leόn,Soe Mar,Andrew Lee,Manu Goyal,Margaret M Reynolds,Gregory P Van Stavern

DOI: https://doi.org/10.1016/j.jcjo.2024.07.021

2024-08-22

Abstract:Background: Whether optical computed tomography (OCT) and magnetic resonance imaging (MRI) findings are associated with final visual acuity in children with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) optic neuritis is unclear. Methods: We retrospectively reviewed the charts of pediatric patients with MOGAD optic neuritis seen at St. Louis Children's Hospital/Barnes Jewish Hospital since 2016. Results: In the 12 patients in this study, presenting visual acuity was worse in the optic neuritis-affected eyes but significantly improved from presentation to follow-up, such that, at last follow-up, there was no longer a statistical difference between the affected and unaffected eyes. The number of affected eyes with nerve enhancement and the amount of optic nerve affected, as well as thickness of the retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), and macula, decreased from presentation to follow-up. Ultimately, none of these variables were associated with final visual acuity. Conclusion: In this cohort, pediatric MOGAD optic neuritis patients had positive visual outcomes despite significant RNFL thinning and involvement of the optic nerve on MRI, leading to a lack of correlation between follow-up visual acuity and OCT and MRI measures of disease severity, respectively.
Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases

Tarin A Europa,Melissa Nel,Maribanyana R Lebeko,Jeannine M Heckmann

DOI: https://doi.org/10.1016/j.ibneur.2022.04.007

2022-04-21

Abstract:Myasthenia gravis (MG) is a rare, treatable, antibody-mediated disease characterized by fatigable muscle weakness of extraocular muscles (EOMs) and non-ocular skeletal muscles. The antibodies are directed against muscle-endplate proteins, most frequently the acetylcholine receptor (AChR) alpha-subunit. Although most MG patients respond to immunosuppressive treatment, some individuals, frequently with African-genetic ancestry, develop treatment-resistant ophthalmoplegia (OP-MG). Although the underlying pathogenetic mechanisms of OP-MG remain unknown, experimental rodent models of MG showed upregulation of genes involved in oxidative metabolism in muscles. EOMs are highly dependent on oxidative metabolism. We opportunistically sampled EOM-tendons of two rare OP-MG patients (and non-MG controls) undergoing re-alignment surgery, and established ocular fibroblast cultures. Metabolic assays were performed on these live cells to assess real-time differences in energy metabolism. To study the cellular bioenergetic profiles in the context of MG, we exposed the cultures to homologous 5% MG sera for 24 h, vs. growth media, from two independent MG patients (with circulating AChR-antibodies) and five controls without MG, and estimated the fold change in oxygen consumption rates in response to three compounds which inhibit different mitochondrial chain complexes. Quantitative PCR (qPCR) was performed in cells before and after MG sera exposure, to assess transcript levels of mitochondrial genes, PDK4, ANGPTL4 and UCP3, which were altered in experimental MG. In response to the mitochondrial stressors, basal oxidative metabolism parameters were similar between OP-MG and control fibroblasts (p = 0.81). However, after exposure to MG sera, bioenergetic parameters (oxygen consumption rate as an indicator of oxidative phosphorylation; extracellular acidification rate as an indicator of glycolysis), were induced to higher levels in OP-MG fibroblasts compared to controls (2.6-fold vs 1.5-fold; p = 0.031) without evidence of mitochondrial insufficiency in the OP-MG ocular fibroblasts. In support of the bioenergetic responses to the same MG sera, gene transcripts of PDK4 and ANGPLT4 in ocular fibroblasts also showed significant upregulation (p ≤ 0.041), but similarly in OP-MG and control cases. Taken together we showed similar basal and metabolic adaptive responses after exposure to mitochondrial inhibitors in ocular fibroblasts derived from OP-MG cases and controls, although the OP-MG cells showed greater activation in response to MG conditions. These pilot results in orbital-derived tissues provide support for myasthenic-induced changes in cellular metabolism and evidence that orbital fibroblasts may be useful for dynamic bioenergetic assessments.
The Pediatric Optic Neuritis Prospective Outcomes Study – Two-Year Results

Stacy L. Pineles,Robert J. Henderson,Michael X. Repka,Gena Heidary,Grant T. Liu,Amy T. Waldman,Mark S. Borchert,Sangeeta Khanna,Jennifer S. Graves,Janine E. Collinge,Julie A. Conley,Patricia L. Davis,Raymond T. Kraker,Susan A. Cotter,Jonathan M. Holmes,Pediatric Eye Disease Investigator Group,Mark S. Borchert,Melinda Y. Chang,Dilshad Contractor,Emily J. Zolfaghari,Aarti Vyas,Tiffany Yuen,Veeral S. Shah,Evelyn A. Paysse,Gihan Romany,Jason H. Peragallo,Judy L. Brower,Aparna Raghuram,Gena Heidary,Bilal Al Wattar,Ryan Chinn,Srishti Kothari,R. Michael Siatkowski,Janine E. Collinge,Maria E. Lim,Alisha N. Brewer,Annette M. Doughty,Sonny W. Icks,Shannon Almeida,Alejandra de Alba Campomanes,Premilla Banwait,Jennifer S. Graves,Leila Hajkazemshirazi,Yizhuo Bastea-Forte,Jennifer K. Arjona,Jeremy Chen,Karen Cooper,Rafif Ghadban,Sophia M. Chung,Oscar A. Cruz,Sangeeta Khanna,Traci A. Christenson,Lisa L. Breeding,Dawn M. Govreau,Beth A. Wallis,Brooke E. Geddie,Julie A. Conley,Elisabeth T. Wolinski,Patricia L. Davis,Indre M. Rudaitis,Jacqueline Twite,Carrie S. Bloomquist,Sarah R. Laboy,Jackie M. Twite,Stacy L. Pineles,Michelle V. Doan,Marianne J. Bernardo,Michael C. Brodsky,John J. Chen,Jonathan M. Holmes,Suzanne M. Wernimont,Lindsay L. Czaplewski,Stacy L. Eastman,Moriah A. Keehn,Debbie M. Priebe,Don L. Bremer,Richard P. Golden,Catherine O. Jordan,Mary Lou McGregor,Rachel E. Reem,David L. Rogers,Amanda N. Schreckengost,Sara A. Maletic,Mays A. Dairi,Laura B. Enyedi,Sarah K. Jones,Navajyoti R. Barman,Robert J. House,David A. Nasrazadani,Sean M. Gratton,Justin D. Marsh,Rebecca J. Dent,Lezlie L. Bond,Lori L. Soske,Padmaja Sudhakar,Christi M. Willen,Deborah Taylor,Nathaniel Q. Moliterno,Michael Nsoesie,Shaista Vally,Paul H. Phillips,Robert S. Lowery,Beth Colon,Nancy L. Stotts,Kelly D. To,Collin M. McClelland,Raymond G. Areaux,Ann M. Holleschau,Kim S. Merrill,Luis H. Ospina,Rosanne Superstein,Maryse Thibeault,Helene Gagnon,Sean P. Donahue,Scott T. Ruark,Lisa A. Fraine,Petrice A. Sprouse,Ronald J. Biernacki,Grant T. Liu,Robert A. Avery,Brian J. Forbes,Imran Jivraj,Anita A. Kohli,Meg M. Richter,Agnieshka Baumritter,Ellen B. Mitchell,Ken K. Nischal,Lauren M. Runkel,Bianca Blaha,Whitney Churchfield,Christina Fulwylie,Melissa W. Ko,Luis J. Mejico,Muhammad Iqbal,Catherine E. Attanasio,Lena F. Deb,Courtney B. Goodrich,Alisha M. Hartwell,Jennifer A. Moore,Lisa Bohra,Alexandra O. Apkarian,Elena M. Gianfermi,John D. Roarty,Leemor B. Rotberg,Susan N. Perzyk,Raymond T. Kraker,Roy W. Beck,Darrell S. Austin,Nicole M. Boyle,Danielle L. Chandler,Patricia L. Connelly,Courtney L. Conner,Trevano W. Dean,Quayleen Donahue,Brooke P. Fimbel,Robert J. Henderson,Amra Hercinovic,James E. Hoepner,Joseph D. Kaplon,Zhuokai Li,Gillaine Ortiz,Julianne L. Robinson,Kathleen M. Stutz,David O. Toro,Victoria C. Woodard,Rui Wu,Michael X. Repka,Laura Balcer,Mark Kupersmith,Elizabeth L. Lazar,Amy Waldman,David K. Wallace,Susan A. Cotter,Eileen E. Birch,Angela M. Chen,Stephen P. Christiansen,S. Ayse Erzurum,Donald F. Everett,Sharon F. Freedman,William V. Good,Katherine A. Lee,Richard London,Vivian M. Manh,Ruth E. Manny,David G. Morrison,Bonita R. Schweinler,Jayne L. Silver,Lisa C. Verderber,Katherine K. Weise,Ari Green,Marie Diener-West,John D. Baker,Barry Davis,Dale L. Phelps,Stephen W. Poff,Richard A. Saunders,Lawrence Tychsen

DOI: https://doi.org/10.1016/j.ophtha.2022.03.021

IF: 14.277

2022-03-01

Ophthalmology

Abstract:PurposePediatric optic neuritis (ON) is a rare disease that has not been well characterized. The pediatric ON prospective outcomes study (PON1) was the first prospective study aiming to evaluate visual acuity (VA) outcomes, including VA, recurrence risk, and final diagnosis 2-years post-enrollmentDesignNon-randomized observational study at 23 pediatric ophthalmology or neuro-ophthalmology clinics in US and Canada.Participants28 (64%) of 44 children initially enrolled in PON1 (age 3<16 years) who completed their 2-year study visit.Exposure(s)Treatment at investigator discretion.Main Outcomes MeasuresAge-normal monocular high contrast VA (HCVA). Secondary outcomes included low contrast VA (LCVA), neuroimaging findings, and final diagnoses.Results28 participants completed the 2-year outcome with a median enrollment age of 10.3 years (range 5-15); 46% were female and 68% had unilateral ON at presentation. Final 2-year diagnoses included isolated ON (n=11, 40%), myelin oligodendrocyte glycoprotein (MOG)-associated demyelination (n=8, 29%), multiple sclerosis (MS) (n=4,14%), neuromyelitis optica spectrum disease (NMOSD) (n=3,11%), and acute disseminated encephalomyelitis (n=2, 7%). Two (7%; 95% CI=1-24%) participants had subsequent recurrent ON (plus one participant who did not complete the 2-year visit); all had MS. Two other participants (7%) had a new episode in their unaffected eye. Mean presenting HCVA was 0.81 logMAR (∼20/125), improving to 0.14 logMAR (∼20/25-2) at 6 months, 0.12 logMAR (∼20/25-2) at 1 year, and 0.11 logMAR (20/25-1) at 2 years (95% CI=-0.08-0.3 (20/20+1-20/40-1)). Twenty-four (79%) had age-normal VA at 2 years (95% CI=60-90%);21 (66%) had 20/20 vision or better. The six participants without age-normal VA had 2-year diagnoses of NMOSD (n=2 participants, 3 eyes), MS (n=2 participants, 2 eyes), and isolated ON (n=2 participants, 3 eyes). Mean presenting LCVA was 1.45 logMAR (∼20/500-2), improving to 0.78 logMAR (∼20/125+2) at 6 months, 0.69 logMAR (∼20/100+1) at 1 year, and 0.68 logMAR (∼20/100+2) at 2 years (95% CI=0.48-0.88 (20/50+1-20/150-1)).ConclusionsDespite poor VA at presentation, most children had marked improvement in VA by 6 months which was maintained over two years. Associated neurologic autoimmune diagnoses were common. Additional episodes of ON occurred in 5 (18%) of the participants (3 relapses and 2 new episodes).

ophthalmology
Ocular aspects of myasthenia gravis

J J Barton,M Fouladvand

DOI: https://doi.org/10.1055/s-2000-6829

Abstract:Ocular myasthenia gravis is a not uncommon autoimmune disorder causing diplopia, ptosis, and weakness of lid closure. The predilection of myasthenia for the ocular muscles may be related to differences between limb and extraocular muscles in either physiological function or antigenicity. Clinically, ocular myasthenia can mimic any form of pupil-sparing ocular motility disorder. Dynamic abnormalities of myasthenic eye movements may reflect the primary hallmarks of the disease, which are fatigability and variability in strength, or secondary adaptive effects by the central nervous system. Tests to confirm the diagnosis include edrophonium challenge, repetitive nerve stimulation, single-fiber electromyography (EMG) of the frontalis, and assays for antibody directed against the acetylcholine receptor: all are less sensitive for ocular myasthenia than for generalized myasthenia. There is a higher incidence of other autoimmune conditions in myasthenia, notably thymoma and thyroid dysfunction. The differential diagnosis includes other diseases of the neuromuscular junction, such as Lambert-Eaton syndrome and botulism. Treatment consists of symptomatic use of acetylcholinesterase inhibitors and immunosuppression with steroids or azathioprine. Between 50 and 70% of patients with ocular myasthenia will eventually develop generalized disease: there is some retrospective data that steroids or azathioprine may reduce this by about 75%. The role of thymectomy in ocular myasthenia remains unclear.
Removal of copper(II) and lead(II) from aqueous solution by manganese oxide coated sand II. Equilibrium study and competitive adsorption.

R. Han,Zhu Lu,Weihua Zou,Daotong Wang,Jie Shi,Jiujun Yang

DOI: https://doi.org/10.1016/J.JHAZMAT.2006.02.018

IF: 13.6

2006-09-01

Journal of Hazardous Materials

Abstract:
Myelin Oligodendrocyte Glycoprotein Antibody Disease Optic Neuritis: A Structure–Function Paradox?

Ruby Ross,Rachel Kenney,Laura J Balcer,Steven L Galetta,Lauren Krupp,Kimberly A O'Neill,Scott N Grossman,Laura J. Balcer,Steven L. Galetta,Kimberly A. O'Neill,Scott N. Grossman

DOI: https://doi.org/10.1097/wno.0000000000002124

2024-03-25

Journal of Neuro-Ophthalmology

Abstract:Background: Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a demyelinating disorder that most commonly presents with optic neuritis (ON) and affects children more often than adults. We report 8 pediatric patients with MOG-associated ON and characterize focal optical coherence tomography (OCT) abnormalities over time that help distinguish this condition from the trajectories of other demyelinating disorders. These OCT findings are examined in the context of longitudinal visual function testing. Methods: This is a retrospective case series of 8 pediatric patients with MOG-associated ON who were referred for neuro-ophthalmic evaluation. Longitudinal data for demographics, clinical history, physical examination, and OCT obtained in the course of clinical evaluations were collected through retrospective medical record review. Results: Patients demonstrated acute peripapillary retinal nerve fiber layer (RNFL) thickening in one or both eyes, consistent with optic disc swelling. This was followed by steady patterns of average RNFL thinning, with 9 of 16 eyes reaching significantly low RNFL thickness using OCT platform reference databases ( P < 0.01), accompanied by paradoxical recovery of high-contrast visual acuity (HCVA) in every patient. There was no correlation between HCVA and any OCT measures, although contrast sensitivity (CS) was associated with global thickness, PMB thickness, and nasal/temporal (N/T) ratio, and color vision was associated with PMB thickness. There was a lower global and papillomacular bundle (PMB) thickness ( P < 0.01) in clinically affected eyes compared with unaffected eyes. There was also a significantly higher N:T ratio in clinically affected eyes compared with unaffected eyes in the acute MOG-ON setting ( P = 0.03), but not in the long-term setting. Conclusions: MOG shows a pattern of prominent retinal atrophy, as demonstrated by global RNFL thinning, with remarkable preservation of HCVA but remaining deficits in CS and color vision. These tests may be better clinical markers of vision changes secondary to MOG-ON. Of the OCT parameters measured, PMB thickness demonstrated the most consistent correlation between structural and functional measures. Thus, it may be a more sensitive marker of clinically significant retinal atrophy in MOG-ON. The N:T ratio in acute clinically affected MOG-ON eyes in our study was higher than the N:T ratio of neuromyelitis optica (NMO)-ON eyes and similar to the N:T ratio in multiple sclerosis (MS)-ON eyes as presented in the prior literature. Therefore, MOG may share a more similar pathophysiology to MS compared with NMO.

ophthalmology,clinical neurology
Pattern Visually Evoked Potentials (pVEPs) and Retinal Nerve Fiber Thickness in a Japanese Girl With Anti-myelin Oligodendrocyte Glycoprotein Antibody Seropositive Optic Neuritis

Midori Tachibana,Shunichiro Takano,Yuri Ohta,Kei Shinoda,Hideo Yamanouchi

DOI: https://doi.org/10.7759/cureus.65254

2024-07-24

Cureus

Abstract:We report our findings in a 5-year-old Japanese girl with unilateral optic neuritis who was seropositive for anti-myelin-oligodendrocyte glycoprotein (MOG) antibody. Functional and microstructural changes were assessed longitudinally for 3.5 years by serial recordings of the pattern visual evoked potentials (pVEPs) and optical coherence tomography (OCT) during the acute and chronic phases. On the initial visit, the best-corrected visual acuity (BCVA) in the right eye was light perception. She was treated with 450 mg of intravenous methylprednisolone pulses followed by a gradual tapering of the oral prednisolone. The visual acuity decreased to no light perception, and plasmapheresis combined with high-dose intravenous immunoglobulin therapy was performed. The BCVA quickly improved to 1.0, and no recurrence was detected for approximately four years. The implicit times of N75, P100, and N145 of the pVEPs and peripapillary retinal nerve fiber (pRNFL) thickness in the OCT images were measured during the course of the disease process. The pRNFL thickness of the right eye decreased and was less than one-half of the baseline value at one year and then stabilized. In contrast, the optic pathway function assessed by pVEPs improved. The implicit times of the N75 and P100 components of the right eye were shortened and stabilized at approximately one year. However, the implicit times in the right eye were still longer than that of the left eye. Our findings documented the course of the function and structures of an eye with anti-MOG antibody-positive optic neuritis. This information should be helpful for the understanding of the pathology and prognosis of this disease entity. Further analysis of the pVEPs and structural changes in more cases is needed.
Pediatric myopic strabismus fixus: clinical features and surgical outcomes of silicone band loop myopexy

Sakshi Lalwani,Virender Sachdeva,Ramesh Kekunnaya

DOI: https://doi.org/10.1080/09273972.2024.2306348

Strabismus

Abstract:Purpose: To evaluate the clinical profile of myopic strabismus fixus (MSF) in children and surgical outcomes of silicone band loop myopexy. Method: We retrospectively reviewed records of children presenting with MSF who underwent silicone band loop myopexy between January 2008 and December 2020 at a tertiary eye care center. Data concerning demographics, refractive error, axial length, extra-ocular motility, and ocular alignment pre-operatively and post-operatively, intra- and post-operative complications, ocular and systemic associations, were evaluated. The long-term effects of band loop myopexy on ocular alignment stability, motility improvement, and myopia progression were analyzed. Surgical outcome was defined as post-operative orthotropia or heterotropia less than or equal to 20 PD. Results: A total of0 eyes of 7 patients (median age: 5 years; 5 boys and 2 girls) who underwent band loop myopexy were included in the study. Among them, three children underwent bilateral and four children underwent unilateral band loop myopexy. Medial rectus recession was performed only in two patients as a part of initial procedure. The median follow-up duration was 7 years. Most of the children, i.e. six of them presented with esotropia-hypotropia and only one patient presented with exotropia-hypotropia complex. The median pre-operative measurements were esotropia of 62.5 PD, hypotropia of5 PD, and exotropia of4 PD. Postoperative average primary position deviation measured was close to 9-10 PD of esotropia. The overall motility improved to -1 from -3. Conclusion: The clinical profile of MSF in children is almost similar to adults. This condition is a rare entity among adults as well as children. Majority of children with MSF presented with esotropia-hypotropia complex. Silicone band loop myopexy with or without medial rectus recession proves to be a reliable surgical procedure as it provides stable outcomes in terms of ocular alignment and motility among children.
Pearls & Oy-sters: Ocular Myasthenia Gravis

Angela Young,Janine L Johnston,Janine L. Johnston

DOI: https://doi.org/10.1212/wnl.0000000000209260

IF: 9.9

2024-03-26

Neurology

Abstract:Myasthenia gravis (MG) has been described as a great mimicker of other neurologic and ocular motility disorders, including centrally mediated ophthalmoplegia. For example, ocular myasthenia gravis (ocular MG) may cause impaired binocular visual acuity for near vision due to reduced accommodation or for distance vision due to accommodative excess. Notably, accommodative excess due to ocular MG is rare, but may occur with exotropia, with or without diplopia. We report 2 cases of ocular MG: First, a 32-year-old man with exotropia, bilateral hypometric and slowed adducting saccades with dissociated abducting nystagmus, miosis, and decreased distance vision in his right eye; second, a 45-year-old man with similar ocular motor deficits, miosis, and myopia. Both patients showed ocular motor deficits which appeared to localize to the pons but were instead due to ocular MG. Ocular MG should be considered in patients who present with reduced visual acuities due to any disruption in accommodation. Any ocular motor deficit, even if appearing to be centrally mediated or occurring without ptosis, may be caused by ocular MG.

clinical neurology
Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis

Juhee Chae,Thanh Tin Nguyen,Sun-Young Oh

DOI: https://doi.org/10.1007/s00415-024-12461-7

2024-05-28

Journal of Neurology

Abstract:Background and Objectives The diagnostic challenge of myasthenia gravis (MG) is exacerbated by the variable efficacy of current testing methodologies, necessitating innovative approaches to accurately identify the condition. This study aimed to assess ocular muscle fatigue in patients with MG using video-oculography (VOG) by examining repetitive saccadic eye movements and comparing these metrics to those of healthy control participants. Methods This prospective, cross-sectional study was conducted at a tertiary care center and involved 62 patients diagnosed with MG (48 with ocular MG and 14 with generalized MG) and a control group of 31 healthy individuals, matched for age and sex. The assessment involved recording saccadic eye movements within a ± 15° range, both horizontally and vertically, at a rate of 15 saccades per minute over a 5-min period, resulting in 75 cycles. Participants were afforded a 3-min rest interval between each set to mitigate cumulative fatigue. The primary outcome was the detection of oculomotor fatigue, assessed through changes in saccadic waveforms, range, peak velocity, latency, and the duration from onset to target, with a focus on comparing the second saccade against the average of the last five saccades. Results In the evaluation of repetitive saccadic movements, patients with MG exhibited a reduced saccadic range and a prolonged duration to reach the target, compared to healthy subjects. Furthermore, a significant elevation in the frequency of multistep saccades was observed among MG patients, with a marked rise observed over consecutive trials. Receiver operating characteristic (ROC) analysis revealed the discriminative performance of multistep saccade frequency, in conjunction with variations in saccadic range and duration from onset to target achievement between the second saccade and the mean of the final five saccades, as effective in distinguishing MG patients from healthy subjects. Although alterations in peak saccadic velocity and latency were less pronounced, they were nevertheless detectable. Discussion The utilization of VOG for repetitive saccadic testing in the diagnosis of MG has demonstrated considerable diagnostic precision. This methodology affords significant accuracy in evaluating ocular muscle fatigue in MG patients, providing class III evidence supportive of its clinical application.

clinical neurology
Influence of redox status of lymphocytes and monocytes on HIV transcription and replication.

M. Gougerot-Pocidalo,F. Aillet,J. Virelizier,N. Israël

DOI: https://doi.org/10.1016/S0171-2985(11)80544-9

IF: 3.152

1995-07-01

Immunobiology

Abstract:
Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis.

Zhi-Xiao Yang,Kai-Li Xu,Hui Xiong

DOI: https://doi.org/10.3892/etm.2015.2256

IF: 2.7

2015-01-01

Experimental and Therapeutic Medicine

Abstract:This study aimed to analyze the clinical characteristics, classification and treatment of childhood myasthenia gravis (MG) and address the prognosis through follow-up. The clinical data of 135 children with MG were grouped according to clinical type and therapeutic drugs, retrospectively analyzed and prospectively monitored. Of the 135 MG patients, 85.2% had type I (ocular type), with only 4.2% progressing to systemic MG; 13.4% had type II (general type); and 1.5% had type III (fulminating type). Relapse occurred in 46.1% of the 102 patients that were followed up. The positive rate for the primary acetylcholine receptor antibody was 40.19%, without significant differences among clinical subtypes. The positive rate of the repetitive nerve stimulation frequency test by electromyography was 37.97%. Decreased expression of CD4(+), CD8(+), or CD3(+) was present in 71% of the patients. Thymic hyperplasia was present in 5.93% of the patients, while 1.48% had thymoma. Steroid treatment was effective in the majority of the patients. Ocular type MG was common in this cohort of patients. The incidence and mortality of myasthenia crisis were low, the presence of concurrent thymoma was rare and only a limited number of children developed neurological sequelae.
Thermal dose and time-temperature factors for biological responses to heat shock.

E. Gerner

DOI: https://doi.org/10.3109/02656738709140402

1987-07-01

International Journal of Hyperthermia

Abstract:The application of hyperthermia in human cancer therapy, especially by radiotherapists who are accustomed to prescribing ionizing radiation treatments in physical dose units, has stimulated workers in this area to consider the possibility and utility of defining a unit of 'thermal dose'. Previous thermal dose definitions have, primarily, been based on biological isoeffect response relationships, which attempt to relate exposure times that elicit a given biological response at one temperature to exposure times at another temperature that elicit the same biological response. This 'equivalent time' method is shown to have certain limitations. For both 42.4 and 45 degrees C hyperthermia, these relationships accurately describe cell survival responses only when the heating rate is rapid (greater than 0.5 degrees C min-1 from ambient to hyperthermic temperature). Further, the form of these isoeffect relationships appears to be temperature range and cell/tissue-type dependent, and it is suggested that these relationships be referred to as a 'time-temperature factor' (TTF) to help distinguish them from possible physical thermal dose definitions. Two physical dose definitions are discussed, one being simply exposure time at some temperature and the other being a more fundamental definition, the free energy change which is a temperature-dependent driving force for chemical reactions.
Immune mediated myasthenia gravis in children, current concepts and new treatments: A narrative review article

Azita Tavasoli

DOI: https://doi.org/10.22037/ijcn.v18i3.45054

Abstract:Myasthenia gravis (MG) is the most frequent transmission disease in the neuromuscular junction. Juvenile myasthenia gravis (JMG) is an autoimmune antibody-mediated disease of postsynaptic endplate defined as MG presentation in patients before the age of 18 years old. While many clinical features of JMG are identical to the adults, there are some significant differences between them regarding presentation, clinical course, antibody level, and thymus histopathology. In JMG, ocular symptoms are more frequent, the clinical course is comparably benign, and the outcome is better than adult MG. Antibodies attack the muscle endplate proteins in the postsynaptic membrane and interfere with transmission. These antibodies in most patients are against the acetylcholine receptors, but they may also be directed toward muscle-specific kinase, lipoprotein-related protein 4, and agrin. Findings show racial influences and genetic effects on the occurrence of JMG. The essential clinical symptom is fatigable weakness of muscles that can be in the form of isolated ocular type or more disseminated weakness. The diagnosis of JMG is essentially clinical, with fluctuating patterns of weakness and easy fatigability, but a series of diagnostic evaluations can confirm the diagnosis. Precise diagnostic evaluation and distinction from congenital myasthenic syndromes is critical. The treatment plan is conducted according to the clinical course (ocular or generalized), antibody type, and disease severity. The mainstay of treatment includes symptomatic therapy, long-lasting immunosuppressive treatment and treatment of myasthenic crisis. Novel medications are introduced and conducted to the specific pathophysiologic mechanisms of the disease, and they are used primarily in the refractory MG.
THE EFFECTS OF REPEATED PROLONGED EXERCISE ON PLASMA GROWTH HORMONE, INSULIN, GLUCOSE, FREE FATTY ACIDS, GLYCEROL, LACTATE AND β‐HYDROXYBUTYRIC ACID IN 13‐YEAR OLD BOYS AND IN ADULTS

B. Eriksson,B. Persson,J. Thorell

DOI: https://doi.org/10.1111/j.1651-2227.1971.tb05715.x

1971-07-01

Abstract:Growth hormone (GH) has been claimed to play a central role in the regulation of the utilization and storage of body energy sources. However, many of the specific effects of G H have not yet been clarified, and it has been shown that a variety of factors can trigger an increase in the release of GH. Examples of specific factors are hypoglycemia (4, 25, 31) and hyperaminoacidemia (2 , 21), stress (7) and muscular work (10, 13, 14, 17, 22, 28) are nonspecific factors. A series of experiments were made to study the interrelationship of G H in the metabolic adjustment to hard, muscular work. The first experiment is reported on here. It deals primarily with workinduced release of G H in relation to “spontaneous” diurnal changes in plasma G H (15). Because of differences in the effects of G H on growth at different ages, both rapidly growing children and adults were included in the series.
Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study

Yanlin Lang,William Robert Kwapong,Lingyao Kong,Ziyan Shi,Xiaofei Wang,Qin Du,Bo Wu,Hongyu Zhou

DOI: https://doi.org/10.3389/fimmu.2023.1029124

IF: 7.3

2023-01-31

Frontiers in Immunology

Abstract:Purpose: To compare the optical coherence tomography (OCT)/OCT angiography (OCTA) measures in patients with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Methods: Twenty-one MOG, 21 NMOSD, and 22 controls were enrolled in our study. The retinal structure [retinal nerve fiber layer (RNFL) and ganglion cell–inner plexiform layer (GCIPL)] was imaged and assessed with the OCT; OCTA was used to image the macula microvasculature [superficial vascular plexus (SVP), intermediate capillary plexus (ICP), and deep capillary plexus (DCP)]. Clinical information such as disease duration, visual acuity, and frequency of optic neuritis and disability was recorded for all patients. Results: Compared with NMOSD patients, MOGAD patients showed significantly reduced SVP density ( P = 0.023). No significant difference ( P > 0.05) was seen in the microvasculature and structure when NMOSD-ON was compared with MOG-ON. In NMOSD patients, EDSS, disease duration, reduced visual acuity, and frequency of ON significantly correlated ( P < 0.05) with SVP and ICP densities; in MOGAD patients, SVP correlated with EDSS, duration, reduced visual acuity, and frequency of ON ( P < 0.05), while DCP density correlated with disease duration, visual acuity, and frequency of ON. Conclusions: Distinct structural and microvascular changes were identified in MOGAD patients compared with NMOSD patients suggesting that the pathological mechanisms are different in NMOSD and MOGAD. Retinal imaging via the SS-OCT/OCTA might have the potential to be used as a clinical tool to evaluate the clinical features associated with NMOSD and MOGAD.

immunology

Visual and systemic outcomes in pediatric ocular myasthenia gravis.

Clinical Characteristics, Disease Course, and Outcomes of Paediatric Patients with Myelin Oligodendrocyte Glycoprotein-Ab Associated Disease: A Retrospective Clinical Study

Treatment Outcomes and Predictive Factors in Pediatric Ocular Myasthenia Gravis

Pediatric Ocular Myasthenia Gravis: Single-Center Experience

[Pediatric myasthenia with ocular involvement]

A single-center retrospective series of OCT and MRI findings in pediatric MOGAD optic neuritis patients

Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases

The Pediatric Optic Neuritis Prospective Outcomes Study – Two-Year Results

Ocular aspects of myasthenia gravis

Removal of copper(II) and lead(II) from aqueous solution by manganese oxide coated sand II. Equilibrium study and competitive adsorption.

Myelin Oligodendrocyte Glycoprotein Antibody Disease Optic Neuritis: A Structure–Function Paradox?

Pattern Visually Evoked Potentials (pVEPs) and Retinal Nerve Fiber Thickness in a Japanese Girl With Anti-myelin Oligodendrocyte Glycoprotein Antibody Seropositive Optic Neuritis

Pediatric myopic strabismus fixus: clinical features and surgical outcomes of silicone band loop myopexy

Pearls & Oy-sters: Ocular Myasthenia Gravis

Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis

Influence of redox status of lymphocytes and monocytes on HIV transcription and replication.

Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis.

Thermal dose and time-temperature factors for biological responses to heat shock.

Immune mediated myasthenia gravis in children, current concepts and new treatments: A narrative review article

THE EFFECTS OF REPEATED PROLONGED EXERCISE ON PLASMA GROWTH HORMONE, INSULIN, GLUCOSE, FREE FATTY ACIDS, GLYCEROL, LACTATE AND β‐HYDROXYBUTYRIC ACID IN 13‐YEAR OLD BOYS AND IN ADULTS

Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study